Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in RAIR-DTC
NCT05007093Phase 2Active, not recruiting
- Start
- Dec 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in differentiated thyroid cancer (DTC). Started Dec 2020; status: active, not recruiting.
02
Drugs
anlotinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT05007093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007093.